Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Current and Potential Therapeutic Options for Infections Caused by Difficult-to-Treat and Pandrug Resistant Gram-Negative Bacteria in Critically Ill Patients
Authors
Keywords
-
Journal
Antibiotics-Basel
Volume 11, Issue 8, Pages 1009
Publisher
MDPI AG
Online
2022-07-27
DOI
10.3390/antibiotics11081009
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Burden of illness in carbapenem-resistant Acinetobacter baumannii infections in US hospitals between 2014 and 2019
- (2022) Jason M. Pogue et al. BMC INFECTIOUS DISEASES
- Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa
- (2022) Laura Corbella et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)
- (2022) Juan José Castón et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
- (2022) Christopher JL Murray et al. LANCET
- Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae
- (2022) Anaïs Eskenazi et al. Nature Communications
- Efficacy of Eravacycline Versus Best Previously Available Therapy for Adults With Pneumonia Due to Difficult-to-Treat Resistant (DTR) Acinetobacter baumannii
- (2022) Courtney J. Scott et al. ANNALS OF PHARMACOTHERAPY
- Safety and efficacy of cefiderocol for off‐label treatment indications: a systematic review
- (2022) Riyan Babidhan et al. PHARMACOTHERAPY
- New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review
- (2022) Angela Raffaella Losito et al. Antibiotics-Basel
- Cefiderocol: Systematic Review of Mechanisms of Resistance, Heteroresistance and In Vivo Emergence of Resistance
- (2022) Stamatis Karakonstantis et al. Antibiotics-Basel
- Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients
- (2021) Barbara Balandin et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Mortality of Pandrug-Resistant Klebsiella pneumoniae Bloodstream Infections in Critically Ill Patients: A Retrospective Cohort of 115 Episodes
- (2021) Matthaios Papadimitriou-Olivgeris et al. Antibiotics-Basel
- Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study
- (2021) Mario Tumbarello et al. CLINICAL INFECTIOUS DISEASES
- Multidrug-resistant Klebsiella pneumoniae: mechanisms of resistance including updated data for novel β-lactam-β-lactamase inhibitor combinations
- (2021) Irene Galani et al. Expert Review of Anti-Infective Therapy
- Carbapenem Resistance in Acinetobacter baumannii, and their Importance in Hospital‐acquired Infections: A Scientific Review
- (2021) Marie Nguyen et al. JOURNAL OF APPLIED MICROBIOLOGY
- Successful treatment of infective endocarditis due to pandrug-resistant Klebsiella pneumoniae with ceftazidime-avibactam and aztreonam
- (2021) Majed F. Alghoribi et al. Scientific Reports
- How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients?
- (2021) Daniele Roberto Giacobbe et al. EXPERT OPINION ON PHARMACOTHERAPY
- Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies
- (2021) Ilias Karaiskos et al. Expert Review of Anti-Infective Therapy
- In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime and meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase producing clinical isolates
- (2021) Joseph Meletiadis et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
- (2021) George L. Daikos et al. Antibiotics-Basel
- The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
- (2021) Carola Mauri et al. Antibiotics-Basel
- Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
- (2021) Alex Soriano et al. Infectious Diseases and Therapy
- Infectious Diseases Society of America Guidance on the Treatment of AmpC β-lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
- (2021) Pranita D Tamma et al. CLINICAL INFECTIOUS DISEASES
- European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
- (2021) Mical Paul et al. CLINICAL MICROBIOLOGY AND INFECTION
- Epidemiology and in vitro activity of ceftazidime–avibactam, meropenem–vaborbactam, imipenem–relebactam, eravacycline, plazomicin, and comparators against Greek carbapenemase-producing Klebsiella pneumoniae isolates
- (2021) Sofia Maraki et al. INFECTION
- Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
- (2021) Nicholas Rebold et al. Open Forum Infectious Diseases
- Systematic Review of Antimicrobial Combination Options for Pandrug-Resistant Acinetobacter baumannii
- (2021) Stamatis Karakonstantis et al. Antibiotics-Basel
- Contemporary Perspective on the Treatment of Acinetobacter baumannii Infections: Insights from the Society of Infectious Diseases Pharmacists
- (2021) Jacinda C. Abdul-Mutakabbir et al. Infectious Diseases and Therapy
- Effectiveness and Safety of High Dose Tigecycline for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis
- (2020) Lei Zha et al. ADVANCES IN THERAPY
- Real-world experience with ceftolozane-tazobactam for multidrug-resistant gram-negative bacterial infections
- (2020) Sarah C.J. Jorgensen et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections
- (2020) Renee Ackley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria
- (2020) Diamantis P. Kofteridis et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Detection in two hospitals of transferable ceftazidime-avibactam resistance in Klebsiella pneumoniae due to a novel VEB β-lactamase variant with a Lys234Arg substitution, Greece, 2019
- (2020) E. Voulgari et al. Eurosurveillance
- Outbreak of KPC-2-producing Klebsiella pneumoniae endowed with ceftazidime-avibactam resistance mediated through a VEB-1-mutant (VEB-25), Greece, September to October 2019
- (2020) Irene Galani et al. Eurosurveillance
- Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections
- (2020) Sara Alosaimy et al. Open Forum Infectious Diseases
- Clinical efficacy and safety of polymyxins based versus non-polymyxins based therapies in the infections caused by carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
- (2020) Cheng Lyu et al. BMC INFECTIOUS DISEASES
- Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by MBL- producing Enterobacterales
- (2020) Marco Falcone et al. CLINICAL INFECTIOUS DISEASES
- Antimicrobial Resistance in ESKAPE Pathogens
- (2020) David M. P. De Oliveira et al. CLINICAL MICROBIOLOGY REVIEWS
- In vitro activity of ceftolozane/tazobactam alone and in combination with amikacin against MDR/XDR Pseudomonas aeruginosa isolates from Greece
- (2020) Irene Galani et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis
- (2020) Yuan-yuan Li et al. BMC INFECTIOUS DISEASES
- Successful Treatment of Pandrug-resistant Klebsiella pneumoniae Infection With Ceftazidime-avibactam in a Preterm Infant
- (2020) Yesim Coskun et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Excess mortality due to pandrug-resistant Acinetobacter baumannii infections in hospitalized patients
- (2020) S. Karakonstantis et al. JOURNAL OF HOSPITAL INFECTION
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
- (2020) Richard G Wunderink et al. LANCET INFECTIOUS DISEASES
- Cefiderocol for compassionate use in the treatment of complicated infections caused by extensively- and pan-resistant Acinetobacter baumannii
- (2020) A. Oliva et al. Journal of Global Antimicrobial Resistance
- In vitro activity of aztreonam-avibactam (ATM-AVI) against a global collection of Klebsiella pneumoniae, collected from defined culture sources, in 2016 and 2017
- (2020) S. Esposito et al. Journal of Global Antimicrobial Resistance
- Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis
- (2020) Jiating Liu et al. Journal of Global Antimicrobial Resistance
- US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)
- (2020) Shabnam Naseer et al. CLINICAL INFECTIOUS DISEASES
- Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study
- (2020) I Karaiskos et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Aztreonam/avibactam activity against clinical isolates of Enterobacterales collected in Europe, Asia and Latin America in 2019
- (2020) Helio S Sader et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
- (2020) Daniele Roberto Giacobbe et al. Infection and Drug Resistance
- High incidence of MDR and XDR Pseudomonas aeruginosa isolates obtained from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial
- (2019) Astrid Pérez et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In vitro activity of imipenem-relebactam against non-MBL carbapenemase-producing Klebsiella pneumoniae isolated in Greek hospitals in 2015–2016
- (2019) Irene Galani et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Use of Ceftazidime-avibactam for the Treatment of Extensively drug-resistant or Pan drug-resistant Klebsiella pneumoniae in Neonates and Children
- (2019) Elias Iosifidis et al. PEDIATRIC INFECTIOUS DISEASE JOURNAL
- Eravacycline, a newly approved fluorocycline
- (2019) Young Ran Lee et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- The “Old” and the “New” Antibiotics for MDR Gram-Negative Pathogens: For Whom, When, and How
- (2019) Ilias Karaiskos et al. Frontiers in Public Health
- RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
- (2019) Johann Motsch et al. CLINICAL INFECTIOUS DISEASES
- Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis
- (2019) Hekun Mei et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance
- (2019) Jessica Carpenter et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria
- (2019) Patrice Nordmann et al. CLINICAL INFECTIOUS DISEASES
- Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections
- (2019) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- In vitro selection of aztreonam/avibactam resistance in dual-carbapenemase-producing Klebsiella pneumoniae
- (2019) Siqiang Niu et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pandrug-resistant Gram-negative bacteria: a systematic review of current epidemiology, prognosis and treatment options
- (2019) Stamatis Karakonstantis et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-Avibactam To Treat Life-Threatening Infections by Carbapenem-Resistant Pathogens in Critically Ill Mechanically Ventilated Patients
- (2019) Vasiliki Tsolaki et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
- (2019) Olexiy Sagan et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Activity of Eravacycline against Gram-Negative Bacilli Isolated in Clinical Laboratories Worldwide from 2013 to 2017
- (2019) Ian Morrissey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
- (2019) Sarah C J Jorgensen et al. Open Forum Infectious Diseases
- Ceftolozane/tazobactam: place in therapy
- (2018) Daniele Roberto Giacobbe et al. Expert Review of Anti-Infective Therapy
- In vitro activity of ceftazidime/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012–15
- (2018) Krystyna M Kazmierczak et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial
- (2018) Mical Paul et al. LANCET INFECTIOUS DISEASES
- Multidrug-Resistant Pseudomonas Infections: Hard to Treat, But Hope on the Horizon?
- (2018) Lynn Nguyen et al. Current Infectious Disease Reports
- Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016
- (2018) Irene Galani et al. Eurosurveillance
- IGNITE4: Results of a Phase 3, Randomized, Multicenter, Prospective Trial of Eravacycline vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections
- (2018) Joseph S Solomkin et al. CLINICAL INFECTIOUS DISEASES
- Ceftolozane/tazobactam for the treatment of serious P. aeruginosa infections: a multicenter nationwide clinical experience
- (2018) Matteo Bassetti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Attributable clinical and economic burden of carbapenem-non-susceptible Gram-negative infections in patients hospitalized with complicated urinary tract infections
- (2018) Y.P. Tabak et al. JOURNAL OF HOSPITAL INFECTION
- Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae
- (2017) M. Souli et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa
- (2017) Pablo A Fraile-Ribot et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp)
- (2017) Alessandra Oliva et al. JOURNAL OF INFECTION
- Bactericidal and synergistic activity of double-carbapenem regimen for infections caused by carbapenemase-producing Klebsiella pneumoniae
- (2016) A. Oliva et al. CLINICAL MICROBIOLOGY AND INFECTION
- Colistin: still a lifesaver for the 21st century?
- (2016) Ilias Karaiskos et al. Expert Opinion on Drug Metabolism & Toxicology
- Epidemiology of infections caused by polymyxin-resistant pathogens
- (2016) Helen Giamarellou INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Unknown
- (2016) Christine L Mandrawa et al. MEDICAL JOURNAL OF AUSTRALIA
- Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia
- (2015) Jose F. Camargo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae
- (2015) Jessica B. Cprek et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin-Resistant Acinetobacter baumannii: Beyond Carbapenem Resistance
- (2015) Zubair A. Qureshi et al. CLINICAL INFECTIOUS DISEASES
- Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study
- (2015) Mario Tumbarello et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Preliminary Study of Colistin versus Colistin plus Fosfomycin for Treatment of Carbapenem-Resistant Acinetobacter baumannii Infections
- (2014) Rujipas Sirijatuphat et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Effectiveness of a Double-Carbapenem Regimen for Infections in Humans Due to Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae
- (2013) Helen Giamarellou et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial
- (2013) Emanuele Durante-Mangoni et al. CLINICAL INFECTIOUS DISEASES
- Double-Carbapenem Therapy for Carbapenemase-Producing Klebsiella pneumoniae
- (2011) Catharine C. Bulik et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy and safety of tigecycline: a systematic review and meta-analysis
- (2011) Dafna Yahav et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Amikacin Monotherapy for Sepsis Caused by Panresistant Pseudomonas aeruginosa
- (2010) B. Layeux et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Acinetobacter baumannii: Emergence of a Successful Pathogen
- (2008) A. Y. Peleg et al. CLINICAL MICROBIOLOGY REVIEWS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now